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Despite comprehensive treatment with surgery, radiation, and chemotherapy, medulloblastoma remains 
the most common malignant brain tumor in children with a ﬁ  ve-year disease free survival rate of only 
40% in those less than 10 years of age. Although adjuvant regimens are an integral component in patient 
management, radiotherapy in very young children is limited by the susceptibility of the immature brain 
to radiation-induced cognitive deﬁ  cits. Thus, the development of an effective adjuvant protocol employ-
ing chemotherapy alone is of substantial interest.
Rutkowski and colleagues published the results of their trial investigating the treatment of medul-
loblastoma solely with postoperative chemotherapy (Rutkowski et al. Treatment of Early Childhood 
Medulloblastoma by Postoperative Chemotherapy Alone. N Engl J Med. 2005;352(10): 978–986). In 
this multi-institutional clinical trial, 43 patients with histologically conﬁ  rmed medulloblastoma were 
treated after surgery with an intensive chemotherapy protocol, consisting of three cycles of intravenous 
cyclophosphamide, vincristine, methotrexate, carboplatin, and etoposide, as well as intraventricular 
methotrexate. Results were as follows: in children with complete resection, partial resection, and 
macroscopic metastases, the ﬁ  ve-year progression-free and overall survival rates were 82% and 93%, 
50% and 56%, and 33% and 38%, respectively. Furthermore, desmoplastic histology, metastatic disease, 
and age less than two years were found to be independent prognostic factors for tumor relapse and 
poor survival. Of note, there were no instances of unexpected toxicity, with only asymptomatic 
leukoencephalopathy occurring in the majority of patients. Although the mean IQ of patients in this 
cohort was signiﬁ  cantly lower than that of healthy, matched controls, it was higher than that of patients 
receiving cerebral radiation. Based on these ﬁ  ndings, the authors concluded that in young children 
without metastases, chemotherapy may be used alone as adjuvant treatment for medulloblastoma, 
especially after gross total resection or those with desmoplastic variants, which portends a more favor-
able prognosis.
This article highlights the growing importance of chemotherapy in the treatment of pediatric brain 
tumors, and represents a substantial step forward in the management of medulloblastoma. In the past, 
postoperative radiotherapy was frequently used in this patient population. Although highly effective, 
the risk of permanent cognitive side effects severely limits its use in children younger than ﬁ  ve years 
of age. In such cases, chemotherapy may be employed to delay neuraxis irradiation. This study, which 
is the largest conducted to date in children 3 years old, demonstrates that patients receiving intensive 
chemotherapy may not only achieve excellent outcomes, but may also avoid the need for radiotherapy 
all together. As expected, cognitive testing in this cohort demonstrated milder side effects from chemo-
therapy than radiotherapy. It is important to note, however, factors other than radiation therapy may 
impact on quality of life and neuropsychiatric development. Regardless, the authors’ ﬁ  ndings have 
implications for the current management guidelines of pediatric CNS malignancies by supporting the 
notion that radiotherapy may be avoided in young children without compromising prognosis.
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Figure 1. A) Sagittal T1-weighted post-contrast MRI demonstrating a medulloblastoma ﬁ  lling the 4th ventricle. B) Histopathology of a 
medulloblastoma demonstrating densely packed cells forming Homer Wright rosettes.